Moving forward with human papillomavirus immunotherapies

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Persistent human papillomavirus (HPV) infection is the primary cause of cervical cancer and contributes to other cancers.
• Current therapeutic HPV vaccine strategies targeting systemic T cell responses have shown limited success in clinical trials.

Purpose of the Study:

• To explore novel strategies for developing effective HPV therapeutic vaccines.
• To address the limitations of existing vaccine approaches by considering the epithelial context of HPV infection.

Main Methods:

• Review of current advances in immunology and vaccine development for HPV.
• Discussion of strategies to enhance T cell trafficking into HPV lesions.
• Emphasis on the need for biologically relevant animal models for preclinical evaluation.

Main Results:

• Limited success of systemic T cell-inducing vaccines against high-grade cervical and vulvar neoplasia.
• Potential advantages of strategies promoting T cell trafficking and overcoming local immunosuppression.

Conclusions:

• Future HPV therapeutic vaccine development should focus on the epithelial context and local immune environment.
• Persistent infections and low-grade lesions may be more amenable targets for therapeutic vaccines.
• Improved animal models are essential for preclinical assessment of vaccine candidates.